Prescription Options for IBS-D: Rifaximin and the Evidence Behind It

What can be prescribed for IBS-D?

Rifaximin, primarily. The ACG's IBS guideline organizes treatment by subtype, and rifaximin is what it recommends for IBS with diarrhea 1Ref 1Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, Moshiree B (2021).ACG Clinical Guideline: Management of Irritable Bowel Syndrome.That IBS treatment is organized by subtype, that rifaximin is the recommended pharmacologic option for IBS with diarrhea, and that gut-directed psychotherapy sits alongside the drug recommendations.. The NIDDK describes IBS with diarrhea as one of the recognized types, distinct from the constipation-predominant and mixed patterns 2Ref 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2017).Symptoms & Causes of Irritable Bowel Syndrome.That IBS with diarrhea is one of the recognized IBS types, distinct from the constipation-predominant and mixed patterns.. That ordering matters: nothing on this page applies until the subtype is settled, because the drugs for the two poles work in opposite directions.

Rifaximin is an antibiotic. Unlike most antibiotics, it is used here as a defined course aimed at a chronic symptom pattern rather than at an identified infection.

The subtype point is not a formality. Prescription drugs for IBS-C are built to move stool along; the IBS-D menu is trying to do something closer to the opposite. Handing someone the wrong one does not produce a disappointing result, it produces a worse week. This is why a clinician will want your actual bowel record — the IBS subtypes are distinguished by stool form over a typical span of weeks, which is what the Bristol stool scale exists to make describable.

It is also why the honest answer to "what can I be prescribed" starts with a question rather than a list.

What the rifaximin trials actually showed

Two phase 3 trials, called TARGET 1 and TARGET 2, tested a two-week course of rifaximin against placebo in people with IBS without constipation. The result was relief of global symptoms and of bloating that reached statistical significance and that the investigators characterized as modest 3Ref 3Pimentel M, Lembo A, Chey WD, et al. (TARGET Study Group) (2011).Rifaximin therapy for patients with irritable bowel syndrome without constipation.That the phase 3 TARGET 1 and TARGET 2 trials tested a two-week course of rifaximin against placebo in IBS without constipation and found modest but statistically significant relief of global symptoms and bloating.. That is the whole evidentiary foundation in one sentence, and it is worth reading twice.

A few things follow from how that study was built:

• The population was IBS without constipation. The evidence speaks to the diarrhea and mixed side. It does not carry over to IBS-C.
• The comparison was placebo, not another drug. These trials say rifaximin beat nothing. They do not rank it against the other things you could try.
• The outcomes were global symptoms and bloating. Those are what improved. A trial answers the question it asked.

None of this is a criticism of the drug. It is the shape of the evidence, and knowing the shape is what lets you tell a reasonable expectation from a hopeful one.

Why "modest" is the most important word here

Because it sets the expectation you will measure the drug against. A modest, statistically significant benefit means the group receiving the drug did better than the group receiving placebo — not that every individual in it improved, and not that those who did improve were cured 3Ref 3Pimentel M, Lembo A, Chey WD, et al. (TARGET Study Group) (2011).Rifaximin therapy for patients with irritable bowel syndrome without constipation.That the phase 3 TARGET 1 and TARGET 2 trials tested a two-week course of rifaximin against placebo in IBS without constipation and found modest but statistically significant relief of global symptoms and bloating.. Some people take a course and notice little. That outcome sits inside what the trial predicts, not outside it.

"Modest" describes an average across a group. It is not a promise made to you, and a disappointing result is not evidence that you were treated badly.

This matters more in IBS than in most conditions, because so many people arrive at the prescription conversation having already been dismissed. When a drug with real trial evidence produces an underwhelming result, the old doubt comes straight back — maybe there was never anything there. There was. Whether IBS is a real condition is not a question a modest effect size reopens; a modest effect size is a fact about a drug, not about a diagnosis.

The practical version: give the course a fair hearing, notice honestly what changed, and treat that as information for the next decision rather than as a verdict on the whole enterprise.

Why it's a course, not a standing prescription

Because that is what was tested. The TARGET trials studied two weeks of treatment rather than continuous use, so the evidence describes a defined course with a beginning and an end 3Ref 3Pimentel M, Lembo A, Chey WD, et al. (TARGET Study Group) (2011).Rifaximin therapy for patients with irritable bowel syndrome without constipation.That the phase 3 TARGET 1 and TARGET 2 trials tested a two-week course of rifaximin against placebo in IBS without constipation and found modest but statistically significant relief of global symptoms and bloating.. This is unusual enough to be worth naming: most drugs for chronic conditions are taken indefinitely, and people are sometimes unsettled to be handed something that deliberately stops.

What happens if symptoms return after the course finishes is a question for the clinician who prescribed it, and it is beyond what the evidence on this page settles. It is a reasonable thing to ask about before starting, though, because the answer shapes how you will feel in week four. Going in expecting a permanent fix and receiving a temporary one reads as failure. Going in knowing it is a course reads as information.

The cost conversation belongs here too, and it is better had upfront than at the pharmacy counter. Coverage for this drug is frequently conditional on documentation of what came before it, which is another reason a clear record of previous trials is worth more than it looks.

What else is on the IBS-D list

More than drugs, and the guideline says so structurally. The NIDDK lists the categories of IBS treatment as dietary change including the low FODMAP diet, more fiber, medicines, probiotics, and mental-health therapies such as CBT, gut-directed hypnotherapy, and relaxation 4Ref 4National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2017).Treatment for Irritable Bowel Syndrome.The enumeration of IBS treatment categories: dietary change including the low FODMAP diet, more fiber, medicines, probiotics, and mental-health therapies including CBT, gut-directed hypnotherapy, and relaxation.. The ACG guideline places gut-directed psychotherapy alongside its drug recommendations rather than after them 1Ref 1Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, Moshiree B (2021).ACG Clinical Guideline: Management of Irritable Bowel Syndrome.That IBS treatment is organized by subtype, that rifaximin is the recommended pharmacologic option for IBS with diarrhea, and that gut-directed psychotherapy sits alongside the drug recommendations..

The menu is wider than the prescription pad, and the guideline's ordering says the non-drug options are not consolation prizes.

A note on the psychological therapies, because the name does real damage. Gut-directed hypnotherapy and CBT appearing on an IBS treatment list is not a coded suggestion that the symptoms are invented. These are treatments aimed at a system that runs in both directions, and they sit in the guideline because trials put them there — the same reason rifaximin sits in it.

Probiotics for IBS appear on the NIDDK's list of categories too. That is a statement that they are part of the landscape, not a statement about how well they work; the efficacy question has its own evidence base and its own answer, and the sources behind this page do not settle it. Anyone telling you confidently in either direction is going beyond what this page can support.

Peppermint oil, and what its evidence actually says

It is not a prescription, but it comes up in every IBS-D conversation, so it deserves an honest line. A meta-analysis of ten randomized trials found peppermint oil superior to placebo for global IBS symptoms and for abdominal pain — while also reporting more adverse events and rating the overall quality of the evidence as very low 5Ref 5Ingrosso MR, Ianiro G, Nee J, et al. (2022).Systematic review and meta-analysis: efficacy of peppermint oil in irritable bowel syndrome.That a meta-analysis of ten randomized trials found peppermint oil superior to placebo for global IBS symptoms and abdominal pain, while reporting more adverse events and very-low-quality evidence.. Both halves of that sentence are the finding.

This is a useful case study in reading evidence, because the two halves get separated constantly. Wellness copy quotes the first half and calls peppermint oil clinically proven. Skeptics quote the second half and call it useless. The meta-analysis says both things at once: a signal that beat placebo, drawn from a body of trials whose quality the authors themselves rated at the bottom of the scale, with more side effects in the peppermint group.

What a person does with that is genuinely a judgement call, and it is a reasonable one to bring to a clinician alongside the prescription question rather than to treat as a separate, unofficial track. Something being available without a prescription does not make it free of consequences — the adverse-event finding is part of the evidence, not a footnote to it.

When diarrhea is not IBS-D

Blood in the stool is not IBS. Nor is diarrhea that wakes you from sleep, nor weight coming off without trying, nor a fever that keeps returning, nor anemia turning up on routine bloodwork. IBS-D describes a specific pattern, and these sit outside it. A diagnosis you already carry does not absorb a new symptom simply because the symptom arrived in the same part of your body.

The timeframes are not vague. Visible blood in the stool warrants an appointment within days rather than at the next routine visit. Diarrhea that pulls you out of sleep is worth an appointment rather than a refill, because IBS is generally a waking-hours pattern and a nocturnal one is a question. Weight loss you did not intend, alongside a change in bowel habit, belongs in front of a clinician now.

The reason to be firm about this on a page about IBS-D drugs is that this is exactly where alarm symptoms get lost. A person with a name for their symptoms and a prescription in hand has every reason to file a new one under the old heading. But the prescription is not the explanation. A treatment that is working on IBS is not evidence that everything happening is IBS.